Shanghai ThermoScientific Biotech Secures Nearly RMB 200 Million in Series B+ Funding to Advance First-in-Class Therapies for Pain, Inflammation, and CNS Disorders

VCBeat learned that on October 18, 2021, Shanghai Sai Murrow Biotechnology Co. Ltd. (hereinafter referred to as “Sai Murrow Biotech” or the “Company”) announced the completion of its Series B+ financing round, raising nearly RMB 200 million. The round was led by Zhangjiang Haocheng and Zhangjiang Haoheng, with follow-on investments from GF Xinde, Yifeng Capital, and Shenzhen Zhongzheng Funeng.

“We are deeply grateful to all investors for their recognition and support of Sai Murrow Biotechnology, which will significantly bolster our ongoing clinical trials of multiple new drug candidates,” said Dr. Li Shuai, Chairman and CEO of Sai Murrow Biotechnology. “The funds raised in this round will be allocated to advancing clinical studies of our products, preclinical basic research, R&D platform development, expansion of our product pipeline, and team growth.”

He Dajun, General Manager of Zhangjiang Hi-Tech, stated, “Sai Murrow is a leading domestic innovator in the research and development of original neurological drugs, equipped with a comprehensive platform for original drug R&D and translation. Its R&D team possesses extensive academic expertise in neuroscience, with a profound understanding of targets and mechanisms, while its translation team brings over a decade of industry experience. We are highly optimistic about the growth and expansion of innovative pharmaceutical enterprises like Sai Murrow, which hold fully independent intellectual property rights, in the fertile ground of Zhangjiang Science City.”

Song Ruomeng, General Manager of the Healthcare Investment Department at GF Xinde, stated: “Sai Murrow is an innovative pharmaceutical research company whose entire pipeline consists of first-in-class drugs. In an environment where medical policies are frequently introduced to encourage China-made indigenous innovation and original research, all of Sai Murrow’s products align with national policy expectations. Furthermore, its core candidates target the indication of pain, differentiating the company from competitors and directly addressing the vast global pain management market. We are honored to participate in this round of investment in Sai Murrow and hope that the company will accelerate its product development process and bring its products to market as soon as possible.”

Zhu Pai, Managing Partner at Yifeng Capital, stated, “Sai Murrow Biotechnology boasts a first-class R&D team, sustained innovation capabilities, and a clear business layout. With pain therapeutics as its core focus, the company is also expanding into inflammation and other nervous system-related diseases. Currently, there is a significant unmet clinical need in pain management. The development of drugs with superior safety and efficacy will benefit a vast number of patients. We look forward to Sai Murrow Biotechnology becoming a leading neurotherapeutics R&D enterprise in China and globally, launching more high-quality drugs, and realizing its corporate vision and value.”

Shanghai Sai Murrow Biotechnology Co. Ltd. is an innovative, value-driven new drug R&D company committed to alleviating and relieving patient suffering and improving quality of life. The company focuses on the development of novel therapeutics for pain, inflammation, and central nervous system-related disorders. Since its establishment in 2014, the company has built a research and development platform spanning over 3,000 square meters, with comprehensive drug development capabilities encompassing compound screening, CMC studies, preclinical evaluation, and clinical development.

Shanghai Zhangjiang Hi-Tech Park Development Co., Ltd. (Zhangjiang Hi-Tech)As the primary developer of Zhangjiang Science City, the core area bearing the mission of Shanghai’s Science and Technology Innovation Center, the Company was established in April 1996 and listed on the Shanghai Stock Exchange (Stock Code: 600895), with a registered capital of RMB 1.549 billion. By creating spatial carriers covering the full lifecycle, the Company provides technology enterprises with comprehensive space solutions ranging from incubation and acceleration to R&D and office operations. Through deploying investment funds across the entire industry chain, it integrates comprehensively into the industrial chain and ecosystem via a model combining “direct investment + funds + 895 Incubator.” Furthermore, by offering innovation services with unlimited connectivity, the Company builds a robust innovation service ecosystem.

Zhang Jiang HaohengAn equity investment management company initiated and established by Zhangjiang High-Tech, focusing on technological innovation enterprises in fields such as integrated circuits, biopharmaceuticals and medical devices, next-generation information technology, and intelligent manufacturing. Rooted in the core industries of Zhangjiang Science City, the company concentrates on “hard tech” sectors, leveraging capital to empower technological innovation. Meanwhile, by drawing on Zhangjiang High-Tech’s rich industrial ecosystem and integrating various innovation elements and resources, it provides diversified support and services to enterprises, including space products, talent acquisition, and policy support.

GF XindeGF Xinde specializes in investment, coaching, financing, and mergers and acquisitions for pre-IPO companies, having successfully assisted numerous outstanding Chinese enterprises in listing on major global stock exchanges. As a vice-chairman unit of the Project Investment and Financing Professional Committee of the China Investment Association, GF Xinde adheres to the development philosophy of aligning the intrinsic value of Chinese enterprises with global capital markets. It has established strong partnerships with major global stock exchanges and professional intermediary institutions, providing specialized coaching and investment and financing services to high-growth Chinese companies.

Yifeng CapitalAs one of the earliest professional biopharmaceutical investment firms in China, Yifeng Capital’s investment team comprises PhDs in biopharmaceutical sciences from top-tier universities both domestically and internationally. The firm specializes in global venture capital (VC) and private equity (PE) investments in the biopharmaceutical sector and has successfully facilitated the public listings of numerous portfolio companies. Owing to its outstanding investment performance and robust investment research capabilities, Yifeng Capital has been honored with titles such as “Top 30 Healthcare Investment Institutions in China” by Zero2IPO, “Top 10 Best Exit Cases in the Biopharmaceutical Sector,” and “China’s Most Dynamic Innovative Drug Investment Institution.” It has also been featured in an exclusive interview by Nature, a world-renowned scientific journal. Yifeng Capital maintains a sharp focus on innovative novel drugs and high-end medical devices, deeply identifying high-potential enterprises, driving the industrialization of scientific and technological achievements through capital empowerment, and striving for the advancement of life sciences.